Items where authors include "Ghil, J"

Article

Smolen, JS, Kang, YM, Yoo, WH et al. (7 more authors) (2020) Radiographic Progression Based on Baseline Characteristics From TNF Inhibitor Biosimilar Studies in Patients With Rheumatoid Arthritis. Arthritis Research and Therapy, 22. 188. ISSN 1478-6354

Smolen, JS, Choe, J-Y, Weinblatt, ME et al. (7 more authors) (2020) Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 6 (1). e001096. ISSN 2056-5933

Girolomoni, G, Feldman, SR, Emery, P et al. (4 more authors) (2018) Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. British Journal of Dermatology, 178 (3). e215-e216. ISSN 0007-0963

Emery, P, Vencovský, J, Sylwestrzak, A et al. (10 more authors) (2017) 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology, 56 (12). pp. 2093-2101. ISSN 1462-0324

Emery, P, Vencovský, J, Sylwestrzak, A et al. (7 more authors) (2017) Long-Term Efficacy and Safety in Patients With Rheumatoid Arthritis Continuing on SB4 or Switching From Reference Etanercept to SB4. Annals of the Rheumatic Diseases, 76 (12). pp. 1986-1991. ISSN 0003-4967

Emery, P, Vencovskỳ, J, Sylwestrzak, A et al. (10 more authors) (2017) A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases, 76 (1). pp. 51-57. ISSN 0003-4967

Emery, P, Vencovsky, J, Ghil, J et al. (2 more authors) (2016) Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: Response to Scheinberg and Azevedo. Annals of the Rheumatic Diseases, 75 (10). e65. ISSN 0003-4967

Emery, P, Vencovskỳ, J, Ghil, J et al. (1 more author) (2016) Response to: ‘Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences’ by Shah. Annals of the Rheumatic Diseases, 75 (9). e61. ISSN 0003-4967

Emery, P, Vencovský, J, Kang, JW et al. (1 more author) (2016) Confirmation on the immunogenicity assay used in the SB4 phase III study: Response to the comments by Meacci et al. Annals of the Rheumatic Diseases, 75 (7). e40. ISSN 0003-4967

Emery, P, Vencovský, J, Ghil, J et al. (1 more author) (2016) Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. Annals of the Rheumatic Diseases, 75 (7). e38-e38. ISSN 0003-4967

Emery, P, Vencovský, J and Ghil, J (2016) Response to: ‘reporting of potential immunogenicity with biologic drugs: clarity and accuracy required’ by Moots et al. Annals of the Rheumatic Diseases, 75 (5). e25. ISSN 0003-4967